{"entity":{"id":"transpara","kind":"drug","name":"Transpara","aka":[],"tldr":"The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.","summary":"Transpara (ScreenPoint Medical, Nijmegen) is CE-marked and FDA 510(k)-cleared for 2D mammography (2018) and digital breast tomosynthesis (2020). It was the software used in the MASAI randomised trial of 80,000 women in Sweden: the interim analysis (Lancet Oncology 2023) reported a cancer detection rate of 6.1 per 1,000 with AI-supported screening versus 5.1 per 1,000 with standard double reading, similar recall rates, and a 44.3% reduction in screen-reading workload. Transpara is deployed in screening programmes in Sweden, Denmark, Germany and elsewhere, and its use as one of two readers is the model the NHS is evaluating in the EDITH trial.","status":"approved","asOf":"2026-09-10","links":[{"label":"MASAI interim analysis (Lancet Oncol 2023)","url":"https://doi.org/10.1016/S1470-2045(23)00298-X"}],"tags":["test"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":[],"companies":["screenpoint-medical"],"institutions":[],"pathways":[],"terms":[],"trials":["masai"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: the AI does not give a diagnosis; a high score prompts closer radiologist review or recall for further imaging, and a low score can let a programme use one human reader instead of two."],"brand":"Transpara","modality":"AI mammography detection and decision-support software","mechanism":"Deep-learning system scores each mammogram or tomosynthesis exam from 1 to 10 for cancer likelihood and marks suspicious regions, usable as a concurrent reader, second reader or triage tool.","approvals":[{"region":"EU","year":2017,"indication":"CE mark, mammography decision support"},{"region":"US","year":2018,"indication":"510(k) clearance, 2D mammography"},{"region":"US","year":2020,"indication":"510(k) clearance, digital breast tomosynthesis"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/transpara/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/"},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/"}],"company":[{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","route":"/companies/screenpoint-medical/"}],"trial":[{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/"}]}}